Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Clinical Medicine, UiT The Arctic University of Norway and Department of Mental Health and Substance Abuse, University Hospital of North Norway, Tromsø, Norway.
Nord J Psychiatry. 2022 Nov;76(8):602-609. doi: 10.1080/08039488.2022.2039288. Epub 2022 Feb 24.
Cardiometabolic disease in patients with severe mental illness is a major cause of shortened life expectancy. There is sparse evidence of real-world clinical risk prevention practice. We investigated levels of assessments of cardiometabolic risk factors and risk management interventions in patients with severe mental illness in the Norwegian mental health service according to an acknowledged international standard.
We collected data from 264 patients residing in six country-wide health trusts for: (a) assessments of cardiometabolic risk and (b) assessments of levels of risk reducing interventions. Logistic regressions were employed to investigate associations between risk and interventions.
Complete assessments of all cardiometabolic risk variables were performed in 50% of the participants and 88% thereof had risk levels requiring intervention according to the standard. Smoking cessation advice was provided to 45% of daily smokers and 4% were referred to an intervention program. Obesity was identified in 62% and was associated with lifestyle interventions. Reassessment of psychotropic medication was done in 28% of the obese patients. Women with obesity were less likely to receive dietary advice, and use of clozapine or olanzapine reduced the chances for patients with obesity of getting weight reducing interventions.
Nearly nine out of the ten participants were identified as being at cardiometabolic high risk and only half of the participants were adequately screened. Women with obesity and patients using antipsychotics with higher levels of cardiometabolic side effects had fewer adequate interventions. The findings underscore the need for standardized recommendations for identification and provision of cardiometabolic risk reducing interventions in all patients with severe mental illness.
严重精神疾病患者的心脏代谢疾病是导致预期寿命缩短的主要原因。目前,关于真实世界临床风险预防实践的证据很少。我们根据公认的国际标准,调查了挪威精神卫生服务中严重精神疾病患者的心脏代谢危险因素评估和风险管理干预水平。
我们从六个全国性健康信托基金中居住的 264 名患者那里收集了数据:(a)心脏代谢风险评估和(b)降低风险干预措施的评估。我们采用逻辑回归来调查风险与干预之间的关系。
50%的参与者完成了所有心脏代谢风险变量的完整评估,其中 88%的参与者根据标准需要进行风险降低干预。45%的每日吸烟者接受了戒烟建议,4%的人被转介到干预计划中。62%的人被诊断为肥胖,并与生活方式干预有关。28%的肥胖患者重新评估了精神药物治疗。肥胖的女性接受饮食建议的可能性较小,而使用氯氮平和奥氮平会降低肥胖患者接受减肥干预的机会。
近十分之九的参与者被认为存在心脏代谢高风险,只有一半的参与者得到了充分的筛查。肥胖的女性和使用具有更高心脏代谢副作用的抗精神病药物的患者接受的适当干预较少。这些发现强调了需要为所有严重精神疾病患者制定标准化建议,以识别和提供心脏代谢风险降低干预措施。